礼来(LLY.N)涨0.14%、诺和诺德(NVO.N)涨0.88%，美国两党议员向美国食品药品监督管理局施压，要求其打击复合及假冒的 GLP-1 类药物。

Group 1 - The article highlights that U.S. bipartisan lawmakers are pressuring the FDA to combat counterfeit and compounded GLP-1 drugs [1] - Eli Lilly (LLY.N) shares increased by 0.14%, while Novo Nordisk (NVO.N) shares rose by 0.88% in response to the news [1]